Curis price target raised to $27 from $15 at JonesResearch

JonesResearch analyst Soumit Roy raised the firm’s price target on Curis to $27 from $15 and keeps a Buy rating on the shares post the Q1 report. The analyst believes there is a pent-up demand for the shares, adding topline data next week in leukemia could reveal the program’s potential. The topline data on May 14 could provide clarity around the path forward and a registration trial design is likely to follow after the FDA meeting, the analyst tells investors in a research note.